Almost every pharma brand team has now tried generative AI for content. Most of them hit the same wall. The drafts arrive in seconds, read well, and then sit in MLR for as long as anything else, because a reviewer still has to check every claim against the label and find a reference for every line. Sometimes they sit longer, because nobody can say where a sentence came from. The speed was real. It just happened in the part of the process that was never the bottleneck.
This guide is for brand, content operations and regulatory teams deciding how to use generative AI for promotional content in 2026. It covers what the rules say, where general-purpose AI tools fail in a regulated setting, what a compliant AI content workflow looks like, and the questions to ask before you put a vendor in front of your MLR team.
Is it legal to use generative AI for pharma promotional content?
Yes. FDA's rules for prescription drug promotion do not depend on how content was made. A banner written by an agency copywriter and a banner drafted by a language model are judged by the same standard: is it truthful and not misleading, is it consistent with the approved labeling, are claims supported by substantial evidence, and is risk information presented with prominence comparable to the benefits. There is no separate approval route for AI content, and no exemption for it either.
That cuts both ways. The company is responsible for everything it disseminates, whoever or whatever wrote the first draft. "The model made it up" is not a defense in an untitled letter. Every asset still goes through MLR review, still gets submitted to FDA on Form FDA 2253 at first use where that applies, and still needs a record of what was approved and why.
Outside the US, check the rules for each market. Europe's AI Act adds transparency obligations for some kinds of AI-generated content, such as synthetic images and video of people, and national codes for medicines advertising apply on top. Your legal team should decide where disclosure is needed. The underlying promotional rules, like the US ones, care about what the content says, not who typed it.
Why do general-purpose AI tools struggle with pharma content?
Because they are built to produce plausible text, and plausible is not the standard. A general-purpose model has read a great deal about your therapy area, including competitor materials, old labels, other markets and outright errors. Ask it for a benefit statement and it will write something that sounds right, drawing on all of that at once. It cannot tell you which approved claim the sentence comes from, because it did not come from one.
The failures reviewers see most are predictable. Efficacy is rounded up or described with a stronger verb than the label supports. The indication drifts wider than the approved population. Risk information is summarized more gently than the label states it. References are attached to sentences they do not support, or invented outright. Each of these is exactly the kind of problem that FDA letters cite.
There is also a data problem. Pasting unpublished trial results, launch plans or a draft label into a consumer AI tool may send confidential information to a third party under terms your company has not agreed to. Most large pharma companies now restrict which AI tools staff can use for this reason, and the restrictions tend to arrive just after a team has built its process around the tool it is no longer allowed to use.
What does a compliant AI content workflow look like?
It starts from approved content, not from the open web. The model writes from a defined source of truth: the current label for the market, the claims your MLR team has already approved with their references, the brand messaging, and the required safety information. If a sentence cannot be traced to one of those sources, it should not be in the draft. This is usually called grounding, and it is the single biggest difference between AI that helps MLR and AI that floods it. The engineering behind it is its own subject: how grounding prevents hallucinations.
Every claim carries its citation. Not a reference list at the end, but a link from each statement to the page, table or figure that supports it, so a reviewer can check it in one click. This is what turns review from re-researching an asset into confirming it.
Checks run before a human sees the draft. Is every claim consistent with the label? Is the indication stated with its limitations? Is the safety information present and as prominent as the benefit content? Has a superiority claim appeared without head-to-head evidence? These checks do not replace reviewers. They stop reviewers spending their time on errors a machine could have caught.
The output goes into your existing review system, with its annotations and references, rather than around it. And the whole trail is kept: which sources were used, which version of the label, what changed between drafts and who approved it. When a label changes, that trail tells you which live assets are affected.
Where AI helps most, and where it should not be used
The clearest gains are in adaptation, not invention. Turning one approved core story into an email, a banner set, a detail aid page, a video script and a web module is slow, repetitive work in which the claims do not change and the format does. That is precisely where grounded AI is strongest, and where the review burden falls fastest, because every format reuses claims the reviewers have already seen.
AI is also useful for the work around content: checking a draft against the label before it goes to review, finding every live asset that uses a claim that is about to change, summarizing reviewer comments across rounds, and localizing approved content for another market with that market’s label and code in place.
It is the wrong tool for creating new claims. A new claim needs a medical, legal and regulatory judgment about what the evidence supports, and that judgment should be made by people, once, and then reused. It is also the wrong tool for deciding whether something is promotional, whether an off-label question has been asked, or whether a risk presentation is balanced. AI can flag these. People decide them.
Questions to ask an AI content vendor
Where does the content come from? Ask to see a draft with every claim traced to its source. If the answer is a general model with a prompt that says "only use approved claims", expect drafts that mostly do and sometimes do not, and expect your reviewers to find out which.
What happens with a claim that is not in the approved library? The right answer is that it does not appear, or that it is flagged as new and routed for review as new. The wrong answer is that the model writes it and the reviewers catch it.
How does it handle fair balance and safety information? Is the required safety information placed in the asset as it is made, in the format the channel needs, or added at the end by a person? How does the tool behave in short formats where space is tight?
Does it work with your review system? If your company uses Veeva PromoMats or another review platform, the output should arrive there with references attached, not as a document someone has to annotate by hand. And who can see your data: is it used to train models for other customers, where is it stored, and can you delete it?
Where SwishX fits
Magic Studio was built for this workflow. It writes every asset, across Video, Docs, Ads, Approved Email and Web, from the claims and dossiers your team has already approved. Every claim is cited to its source and checked against the label for its market, fair balance and safety information are placed in the asset as it is made, and anyone can ask an asset where a line came from. Finished work goes into your MLR queue and on into Veeva PromoMats, rather than around it.
The point is not to make review disappear. It is to make sure that what reaches your reviewers has already been held to their standard, so the time AI saves at the start is not spent again at the end.
Frequently asked questions
Can pharma companies use ChatGPT to write promotional content?
There is no rule against it, but the company is fully responsible for the result, and general-purpose tools are not grounded in approved claims or the label. Many companies also restrict them because confidential information entered into a consumer tool may be shared with a third party. Purpose-built tools that write only from approved sources are a safer route.
Does FDA require disclosure of AI-generated pharma advertising?
FDA's promotional rules apply to content whatever its origin, and there is no separate approval process for AI-generated material. Disclosure rules for synthetic images, voices or people vary by jurisdiction, including under Europe's AI Act, so check with your legal team for each market.
Can AI replace MLR review?
No. Medical, legal and regulatory reviewers make judgments about evidence, balance and context that remain a human responsibility. AI can make review faster by checking drafts against the label, citing every claim and catching routine errors before a reviewer sees the asset.
What is grounded generation in pharma content?
Grounded generation means the AI writes only from a defined set of approved sources, such as the label, the approved claims library and required safety information, and every claim in the output can be traced to the source that supports it.
Where does generative AI save the most time in pharma marketing?
In adapting approved content into many formats and markets: emails, banners, detail aids, video scripts and web pages built from the same approved claims. Because the claims do not change, review is faster as well as production.